drugset / Trial / NCT01759511
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.
Timeline
- Start
- 2012-10-18
- Primary completion
- 2016-02-19
- Completion
- 2016-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Simtuzumab | Monoclonal antibody | 125 mg/ml | Intravenous |
| Subject | Simtuzumab | Monoclonal antibody | 200 mg/ml | Intravenous |